SIK Inhibitor Compounds for Bone Formation Without Daily Injections

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current bone anabolic treatments for osteoporosis, such as parathyroid hormone (PTH) analogs, require daily injections and pose risks like hypercalcemia and osteosarcoma, limiting their widespread use.

Innovation Solution

Development of compounds that modulate the activity of salt inducible kinases (SIKs) to treat diseases related to osteoporosis, offering a potential alternative to PTH analogs with improved safety and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If PTH analogs are used for bone anabolic treatment, then bone formation and bone mass are increased, but the treatment requires daily injections and carries risks ofhypercalcemia and osteosarcoma

Engineering Contradiction:

Improvebone massVSAvoiddaily injection requirement

Core Design Contradiction:

StrengthVSEase of operation

Solution Approach 1:

The patent changes the pharmacokinetic parameters of the treatment by developing SIK inhibitors with longer half-lives and different metabolic profiles compared to PTH analogs. This allows for less frequent dosing (e.g., weekly or monthly oral administration) while maintaining bone anabolic effects, thereby resolving the contradiction between achieving bone mass increase and avoiding daily injections

Inventive Principle:

Principle #35Parameter changes

2Strength

If PTH analogs are used for bone anabolic treatment, then bone formation is increased, but the risk ofhypercalcemia and osteosarcoma increases

Engineering Contradiction:

Improvebone formationVSAvoidhypercalcemia and osteosarcoma risk

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent changes the biochemical parameters of the treatment mechanism by inhibiting SIK enzymes, which leads to increased cAMP levels and activation of PKA signaling pathway. This alternative mechanism achieves bone anabolic effects through a different biochemical pathway that does not carry the same risks ofhypercalcemia and osteosarcoma associated with direct PTH analog administration

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces SIK inhibitors as intermediary compounds that indirectly activate the same downstream signaling pathways as PTH but through a different upstream mechanism. By using SIK as the target rather than directly administering PTH, the treatment achieves bone formation benefits while avoiding the harmful effects associated with direct PTH receptor activation

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12600719B2Salt inducible kinase inhibitors

Publication Date: 2026.04.14 THE GENERAL HOSPITAL CORP

AI summary

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.